1. Scrip
  2. >>Business

Tocagen Aims Double Barrels At Glioma

 
• By Mike Ward

Emerging Company Profile: Gene therapy technology company Tocagen has glioma in its sights. Marty Duvall, newly appointed CEO of the San Diego-based firm, tells Mike Ward how his company’s approach has potential to double survival in one of the deadliest diseases, for which little to no effective treatments exist.

EmergingCompanyProfiles_1200px

Speaking in the hallway at the 2017 Biotech Showcase, Marty Duvall revealed that Tocagen Inc. has developed a double-barreled approach that involves pairing Toca FC (extended-release 5-fluorocytosine), an inactive prodrug, with Toca 511 (vocimagene amiretrorepvec), a modified virus that infects the tumor and delivers an enzyme, which then activates the drug and allows it to kill the glioma cells.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.